Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
1. April 2025
2 min to read

First Objective Definition of Hyperacute T-waves as a ST-segment Elevation Myocardial Infarction Equivalent ECG Finding

Overview

This abstract introduces the first objective definition of hyperacute T-waves (HATW) — an early and often missed ECG sign of a severe heart attack. By accurately detecting blocked arteries even before classic signs appear, the new formula helps doctors identify high-risk patients sooner and deliver life-saving treatment faster.

Published In: Journal of the American College of Cardiology (JACC) – presented at the annual ACC’25 conference
Published Date: April 1, 2025

Background

The American College of Cardiology recommends identifying hyperacute T waves (HATW) as a STEMI equivalent indicating the need for immediate invasive reperfusion strategy. Although HATW have been qualitatively described, they have no objective or quantifiable definition.

Methods

We developed a HATW rule to detect acute coronary occlusion in the absence of STEMI criteria by exploring a database of 12-lead ECGs of acute coronary syndrome patients with known angiographic outcomes. The rule applies to narrow QRS complex rhythms and requires 2 contiguous leads with both: 1) increased ratio of T-wave area to QRS amplitude (using lead-specific ratio thresholds), and 2) increased T-wave symmetry defined as T-wave peak at ≤ 67% of the J-T interval.

Results

1,333 ECGs from 605 patients (130 ECGs meeting formal STEMI criteria) were evaluated. The HATW formula demonstrated 37% sensitivity 98% specificity for acute coronary occlusion myocardial infarction among all patients, and 23% sensitivity and 98% specificity in patients without formal STEMI criteria.

Conclusion

This is the first quantitative analysis of HATW demonstrating its potential as a highly specific STEMI equivalent ECG finding of acute coronary occlusion. Further prospective validation of its performance is warranted.


Authors: Harvey Meyers, Frantisek Simancik, Anthony Demolder, Robert Herman, Timea Kisova, Adam Rafajdus, Jozef Bartunek, Emanuele Barbato, Stephen W. Smith

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Artificial intelligence-enhanced ECG detection of acute coronary occlusion in chest pain patients with ST-elevation in lead aVR – A direct comparison to conventional ECG criteria

In a single‑centre retrospective study of 145 consecutive emergency‑department patients whose first ECG showed ≥1 mm ST‑elevation in lead aVR, investigators compared conventional electrocardiographic rules with a deep‑learning classifier (PMcardio “Queen of Hearts”) for recognising an acute coronary occlusion (ACO). Angiography and biomarker adjudication proved ACO in 19 patients (13 %). At an optimised probability threshold, the AI system achieved an area‑under‑the‑ROC curve of 0.918, detected 63 % of occlusions, and—crucially—generated no false‑positive calls in the 54‑patient rule‑out subgroup. By contrast, classic STEMI millimetre criteria identified only one in four occlusions and would have prompted between four and fourteen unnecessary emergency catheterisations.

AI-enhanced recognition of occlusions in acute coronary syndrome (AERO-ACS): a retrospective study

In a one‑year, single‑centre cohort of 217 cath‑lab patients (72 STEMI, 145 NSTEMI), the AERO‑ACS study tested PMcardio’s AI ECG against traditional ST‑elevation rules for detecting angiographic occlusion‑MI. The algorithm matched STEMI sensitivity (86.5 % vs 83.3 %) while raising specificity to 82.2 % (vs 66.0 %), achieved 100 % sensitivity in STEMI cases, and flagged occlusions linked to a 12‑fold higher in‑hospital mortality risk—suggesting more accurate triage with fewer unnecessary activations.

Join over 100,000 healthcare professionals who are already taking advantage of AI